Thiazolidinedione therapy: The benefits of aggressive and early use in type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 5, Issue 4, 2003, Pages 685-693

  Reusch, Jane E B ^a,b   Gadsby, Roger ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER TOXICITY; MICROANGIOPATHY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; REPRODUCIBILITY OF RESULTS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 0042663907     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091503322250703     Document Type: Review

References (48)

1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
2. Bretzel RG, Voigt K, Schatz H: The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1998;106:369-372.
3. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23). Br Med J 1998;316:823-828.
4. European Diabetes Policy Group: A desktop guide to type 2 diabetes. Diabet Med 1999;16:716-730.
5. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2001;24(Suppl 1):S33-S43.
6. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012.
7. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-368.
8. UK Prospective Diabetes Study (UKPDS) Group: UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258.
9. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR: Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998;15:290-296.
10. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-980.
11. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R, Muggeo M: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25:1135-1141.
12. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Bonadonna RC, Muggeo M: Prevalence rates, additional clinical features and risk of atherosclerosis in subjects with isolated insulin resistance and in subjects with the plurimetabolic syndrome [abstract]. Diabetes 2000;49(Suppl 1):A385.
13. Kobayashi M: Effects of current therapeutic interventions on insulin resistance. Diabetes Obes Metab 1999;1(Suppl 1):S32-S40.
14. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996;137:4189-4195.
15. Scheen AJ, Letiexhe MR, Lefebvre PJ: Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. Diabet Med 1995;12:985-989.
16. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM: The insulin sparing action of troglitazone in intensively treated NIDDM patients exceeds that of metformin [abstract]. Diabetes 1998;47(Suppl 1):A17.
17. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001;44:2210-2219.
18. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-719.
19. Jones TA, Sautter M, Van Gaal LF, Jones NP: Addition of rosiglitazone to metformin is most effective in obese, insulin resistant patients with type 2 diabetes. Diabetes Obes Metab 2003;5:163-170.
20. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN: Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000;17:40-47.
21. Jones NP, Mather R, Owen S, Porter LE, Patwardhan R: Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin [abstract]. Diabetologia 2000;43(Suppl 1):A192.
22. Matthews DR: Insulin resistance and β-cell function - a clinical perspective. Diabetes Obes Metab. 2001;3 (Suppl 1):S28-S33.
23. Miyazaki Y, Matsuda M, DeFronzo RA: Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002;25:517-523.
24. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-1702.
25. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-1409.
26. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-17.
27. Scheen AJ: Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001;24:873-888.
28. Lebovitz HE, Kreider M, Freed MI: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002;25:815-821.
29. Bando Y, Ushiogi Y, Okafuji K, Toya D, Tanaka N, Fujisawa M: Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors. J Int Med Res 1999;27:53-64.
30. King AB: A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000;23:557.
31. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-288.
32. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-1480.
33. Barnett AH: Insulin-sensitizing agents - thiazolidinediones (glitazones). Curr Med Res Opin 2002;18 (Suppl 1):s31-s39.
34. Virtanen KA, Hällsten K, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, Ronnemaa T, Nuutila P: Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003;52:283-290.
35. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791.
36. Cranmer H, Jones NP, Patwardhan R: Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes [abstract]. Diabetologia 1999;42(Suppl 1):A228.
37. Osei K, Miller E, Everitt D, Ilgenfritz J, Porter L, Freed M: Rosiglitazone is effective and well tolerated as monotherapy in African Americans with type 2 diabetes [abstract]. Diabetes 2001;50(Suppl 2):A127.
38. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE: The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-423.
39. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD, The Rosiglitazone Study 108 Investigators: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947-952.
40. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI: Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003;17:7-12.
41. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
42. Albert MA, Ridker PM: The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 1999;1:99-104.
43. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
44. phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect [abstract]. Diabetes 2001;50(Suppl 2):A68.
45. Freed M, Fuell D, Menci L, Heise M, Goldstein B: Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes [abstract]. Diabetologia 2000;43(Suppl 1):A267.
46. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-1820.
47. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
48. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS: The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998;21:701-705.